• No results found

Prognosis in monoclonal proteinaemia Schaar, C.G.

N/A
N/A
Protected

Academic year: 2021

Share "Prognosis in monoclonal proteinaemia Schaar, C.G."

Copied!
7
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

Citation

Schaar, C. G. (2006, November 9). Prognosis in monoclonal proteinaemia. Retrieved from https://hdl.handle.net/1887/4983 Version: Corrected Publisher’s Version

License: Licence agreement concerning inclusion ofdoctoral thesis in the Institutional Repository of the University of Leiden

Downloaded from: https://hdl.handle.net/1887/4983

Note: To cite this publication please use the final published version (if

(2)
(3)

©2006 C.G. Schaar, Leiden, the Netherlands

All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission from the copyright owner.

ISBN-10: 90-77487-40-9 ISBN-13: 978-90-77487-40-2 Book design: Jan Faber

(4)

Prognosis in

Monoclonal

Proteinaemia

Proefschrift ter verkrijging van

de graad van Doctor aan de Universiteit Leiden, op gezag van de Rector Magnificus dr. D.D. Breimer,

hoogleraar in de faculteit der Wiskunde en Natuurwetenschappen en die der Geneeskunde,

volgens besluit van het College van Promoties te verdedigen op donderdag 9 november 2006

klokke 16:15 uur

door

Cornelis Gerardus Schaar Geboren te Port Harcourt, Nigeria,

(5)

Prof. Dr. R. Willemze

Referent

Prof. Dr. P. Sonneveld, Erasmus Universiteit Rotterdam

Overige leden

Prof. Dr. J.H. Bolk

Prof. Dr. J.H.F. Falkenburg Prof. Dr. W.E. Fibbe Prof. Dr. E.M. Noordijk

(6)

5

Table of contents

Chapter 1 Introduction 7

Chapter 2 Serum interleukin-6 has no discriminatory role in

paraproteinaemia nor a prognostic role in multiple myeloma 31 British Journal of Haematology 1999; 107: 132-138

Chapter 3 Serum syndecan-1 in newly diagnosed monoclonal proteinaemia 49 Haematologica/The Hematology Journal 2005; 90: 1437-1438

Chapter 4 Monoclonal proteinaemia and solid tumours

The European Journal of Cancer 2004; 40: 1539-1544 Chapter 5 Long term follow-up of a population based cohort with

monoclonal proteinaemia 65 Submitted

Chapter 6 Early response to therapy and survival in multiple myeloma 83 British Journal of Haematology 2004; 125: 162-166

Chapter 7 Interferon-α as maintenance therapy in patients with

multiple myeloma 95

Annals of Oncology 2005; 16: 634-639

Chapter 8 Summary and general discussion 107

Samenvatting en discussie 121

Appendices 131

Acknowledgements 133

Members of the Paraprotein Taskforce 135

Hospitals in the region of the CCCW 135

Curriculum vitae 137

List of publications 139

(7)

new discoveries, is not ‘Eureka!’ (I found it!) but ‘That’s funny ...’.

Isaac Asimov

Aan Yvonne, Lisette, Céline en Florence Aan mijn moeder

Referenties

GERELATEERDE DOCUMENTEN

We determined interleukin-6 (IL-6) in serum of 212 well-defined patients with newly diagnosed paraproteinaemia and evaluated its discriminatory value and its prognostic role in

No M-protein in serum and/or urine with immunofixation c Single area of bone destruction due to clonal plasma cells Bone marrow not consistent with multiple myeloma Normal

We determined interleukin-6 (IL-6) in serum of 212 well-defined patients with newly diagnosed paraproteinaemia and evaluated its discriminatory value and its prognostic role in

Serum syndecan-1 was investigated in 189 patients with newly diagnosed monoclonal proteinaemia (MM (66), MGUS (54), provisional MGUS (no bone marrow examina- tion performed; 69)) and

’Solid Tumour Group’ versus ‘M-proteinaemia Only Group/MGUS’ To study whether patients with M-proteinaemia and a solid tumour (i.e. ‘Solid Tumour Group’) had

In a previous study, using our database that also included a large number of patients with multiple myeloma, we devised a Myeloma Risk Score using the M-protein serum level and

Therefore, the relation between survival and the rate of monoclonal protein (M-protein) decrement during the first cycles of therapy was prospectively assessed in 262 patients

Background: The effect of interferon- α 2b (IFN-α) on progression free and overall survival as well as quality of life was studied in mainly elderly patients with multiple myeloma